403838-57-3

Basic information

• Product Name: 3-Quinolinecarboxylic acid, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-6-cyano-8-ethyl-, ethyl ester
• CAS NO: 403838-57-3
• Molecular Formula: C23H22ClN3O3
• Molecular Weight: 423.899
• Mol File: 403838-57-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-Quinolinecarboxylic acid, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-6-cyano-8-ethyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Quinolinecarboxylic acid, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-6-cyano-8-ethyl-, ethyl ester(403838-57-3)
• EPA Substance Registry System: 3-Quinolinecarboxylic acid, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-6-cyano-8-ethyl-, ethyl ester(403838-57-3)

Safety Data

• Hazardous Substances Data: 403838-57-3(Hazardous Substances Data)

Upstream product

• 1233518-57-4 ethyl 8-bromo-4-chloro-6-cyanoquinoline-3-carboxylate 
• 4433-63-0 Ethyl boronic acid 
• 1233518-58-5 Ethyl 8-bromo-4-[(3-chloro-4-methoxybenzyl)amino]-6-cyanoquinoline-3-carboxylate 
• 403841-85-0 6-cyano-8-ethyl-4-hydroxy-quinoline-3-carboxylic acid ethyl ester 
• 41965-95-1 (3-chloro-4-methoxyphenyl)methylamine hydrogen chloride 
• 403841-89-4 4-chloro-6-cyano-8-ethyl-quinoline-3-carboxylic acid ethyl ester 
• 690631-28-8 2-[(4-cyano-2-ethyl-phenylamino)-methylene]-malonic acid diethyl ester 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 

Downstream Products

• 403839-09-8 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-6-cyano-8-ethyl-3-quinolinecarboxylic acid 

Relevant articles and documents

Synthesis and in?vitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes

The increasing incidence of Alzheimer's disease (AD) worldwide is a major public health problem. Current treatments provide only palliative solutions with significant side effects. Therefore, new efficient treatment options and novel early diagnosis tools are urgently needed. Recently, strong pre-clinical evidences suggested that phosphodiesterase 5 (PDE5) may be clinically relevant both as biomarker and drug-target in AD. In this study, we intended to develop a new radiofluorinated tracer for the visualisation of PDE5 in brain using PET imaging. Based on currently known PDE5 inhibitors, a series of novel fluorinated compounds bearing a quinoline core have been synthesised via multi-steps reaction pathways. Their affinity for PDE5 and selectivity over other PDE families have been investigated. According to the data collected from this in vitro screening, fluorinated derivatives 24a, b bearing a fluoroethoxy group at the C-3 position of the quinoline core appeared to be the most promising structures and will be further radiolabelled with fluorine-18 for in vitro and in vivo evaluations as PET radiotracer for neuroimaging of PDE5.